AVTX
Avalo Therapeutics, Inc.
There isn't enough reported data to score AVTX yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AVTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
AVTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AVTX PE Valuation
AVTX has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AVTX Forward outlook
There aren't enough analyst estimates for AVTX to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AVTX Earnings Per Share
AVTX and HIMS do not have enough comparable growth data to identify a winner.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AVTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $59K | -69% |
| Q4 2024 | $192K | -66% |
| Q3 2024 | $249K | +5.5% |
| Q4 2023 | $571K | -36% |
| Q3 2023 | $236K | -98% |
| Q2 2023 | $643K | -38% |
| Q1 2023 | $475K | -60% |
| Q4 2022 | $896K | +309% |
AVTX's revenue has slid since its 2022 peak: $59,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -33461% | -26528 points |
| Q4 2024 | -6933% | -5592 points |
| Q3 2024 | -5165% | -3576 points |
| Q4 2023 | -1341% | -353 points |
| Q3 2023 | -1589% | -1616 points |
| Q2 2023 | -1112% | +33 points |
| Q1 2023 | -1851% | -73 points |
| Q4 2022 | -988% | +7214 points |
AVTX's operating margin was −33461% last quarter, down 31872 points from the same quarter a year ago, near the bottom of its range since 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AVTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$11.5M | +$4.8M |
| Q2 2026 | -$20M | -$8.6M |
| Q1 2026 | -$17.7M | -$8.2M |
| Q4 2025 | -$14.2M | +$798K |
| Q3 2025 | -$16.4M | -$4.8M |
| Q2 2025 | -$11.4M | +$4.9M |
| Q1 2025 | -$9.5M | -$3.3M |
| Q4 2024 | -$15M | -$12.3M |
AVTX has burned cash in almost every quarter: −$63M over the past year, against −$52M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over AVTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
AVTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +11.5M shares |
| 1 year | +408% | +44.2M shares |
AVTX has 55M diluted shares, up 408% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AVTX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AVTX Net Leverage
AVTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AVTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 5.1 | Oversold |
AVTX's weekly RSI is 31 (neutral) and its Stochastic is 5 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AVTX PE vs Healthcare Sector
AVTX has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AVTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.5 | 27% below |
| 20 week MA | $15.4 | 50% below |
| 50 week MA | $15.7 | 51% below |
| 100 week MA | $12.2 | 37% below |
| 200 week MA | $96.8 | 92% below |
AVTX is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AVTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14,774.4 | $7,920.0 | -46% |
| 2021 | $7,920.0 | $5,356.8 | -32% |
| 2022 | $5,356.8 | $1,202.4 | -78% |
| 2023 | $1,202.4 | $9.10 | -99% |
| 2024 | $9.10 | $8.33 | -8.5% |
| 2025 | $8.33 | $18.4 | +121% |
| 2026 YTD | $18.4 | $7.70 | -58% |
AVTX's yearly returns have swung widely, from +121% in 2025 to −99% in 2023. It's down 58% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over AVTX on returns for 2026, with the stronger performance.